about
SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasisNovel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infectionsGlibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasisCrystal structure of theLeishmania majorMIX protein: A scaffold protein that mediates protein-protein interactionsStructure of the Trypanosoma cruzi protein tyrosine phosphatase TcPTP1, a potential therapeutic target for Chagas’ diseaseDevelopments in the treatment of visceral leishmaniasisEffect of alkylphospholipids on Candida albicans biofilm formation and maturationNifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case seriesDolabelladienetriol, a compound from Dictyota pfaffii algae, inhibits the infection by Leishmania amazonensisMolecular dynamics reveal binding mode of glutathionylspermidine by trypanothione synthetaseAntileishmanial activity of semisynthetic lupane triterpenoids betulin and betulinic acid derivatives: synergistic effects with miltefosineCrovirin, a snake venom cysteine-rich secretory protein (CRISP) with promising activity against Trypanosomes and LeishmaniaBiological Activity of Coumarin Derivatives as Anti-Leishmanial AgentsNovel sterol metabolic network of Trypanosoma brucei procyclic and bloodstream formsAnti-plasmodial and anti-leishmanial activity of conformationally restricted pentamidine congeners.Infectivity of Leishmania mexicana is associated with differential expression of protein kinase C-like triggered during a cell-cell contactDiscovery of novel benzoxaborole-based potent antitrypanosomal agents.New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugsFacile Synthesis and Preliminary Structure-Activity Analysis of New Sulfonamides Against Trypanosoma bruceiErgosterol isolated from the basidiomycete Pleurotus salmoneostramineus affects Trypanosoma cruzi plasma membrane and mitochondria.Beta-carboline-3-carboxamide derivatives as promising antileishmanial agents.A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome.Antileishmanial, antitrypanosomal, and cytotoxic screening of ethnopharmacologically selected Peruvian plants.2,3-diphenyl-1,4-naphthoquinone: a potential chemotherapeutic agent against Trypanosoma cruzi.Risedronate metal complexes potentially active against Chagas disease.High-content imaging for automated determination of host-cell infection rate by the intracellular parasite Trypanosoma cruzi.Aurones: a promising heterocyclic scaffold for the development of potent antileishmanial agents.Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by "amitochondriate" protozoan parasites.Drug strategies targeting CYP51 in neglected tropical diseasesCameroonian medicinal plants: pharmacology and derived natural productsPharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.Evaluation of α,β-unsaturated ketones as antileishmanial agents.New organoruthenium complexes with bioactive thiosemicarbazones as co-ligands: potential anti-trypanosomal agents.Searching for new chemotherapies for tropical diseases: ruthenium-clotrimazole complexes display high in vitro activity against Leishmania major and Trypanosoma cruzi and low toxicity toward normal mammalian cells.Identification of novel Trypanosoma cruzi prolyl oligopeptidase inhibitors by structure-based virtual screening.In vitro and in vivo studies of the trypanocidal activity of four terpenoid derivatives against Trypanosoma cruziMulticomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activitySafety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults
P2860
Q21144510-FFFC41B8-DBA7-4DC0-839F-245811B0F691Q24311803-5D7A71DF-CCA6-4769-AEC0-575FF89B1071Q24648110-51777116-F147-4D6C-900E-EC17A305BF6AQ24674183-D8CC5516-5139-4A46-9629-332A87349FE7Q27667434-84D9D4F2-C77E-4371-8D56-487FD9A09900Q27675033-D7740983-0E49-4321-9207-70FFB8B35822Q28256441-269A4669-9C5B-4EC6-94E2-CF7DEBC4B97DQ28275463-66CC5D98-33A9-42E6-8BBE-3501F182A089Q28471706-9B0C05BB-1DFD-41F0-8F4E-A01F8E1EEBB4Q28483511-BC66D5A9-A411-4EF7-841B-F853F21E94D9Q28486718-2B05016B-2CFA-47CC-8864-5FBAC934AEA7Q28541041-7250838D-46DC-4BB6-9C28-74E2DA33A169Q28543840-7D19C526-EC57-43E8-A166-3C02DA03EF0EQ28552879-6ED5357E-73BB-4B7D-A28A-A1EB65E65B78Q28714212-6D720CF0-5ACA-45B0-BD5F-529EC84619F6Q33252044-6D1907E8-FF13-42C8-885C-EDB67E30E6A9Q33511990-46B1B2A9-3762-45D3-B0A2-86E688CC207DQ33557952-57B20A6B-68EF-434A-A8D7-EC61B65F6563Q33622982-0F73D438-D1C2-494A-9D2C-339B54A4783DQ33636542-3EBD9489-2264-4AAA-90EF-947744C11552Q33743694-EE051395-603E-4C57-8579-7578FECD5835Q33873641-8EE9A4BD-D2EE-4526-B842-541BB8B4FFE8Q33876638-CCC784A3-31F2-4C69-9678-4A0752E5603BQ33955428-C4BAE27D-CCAC-4A8D-B253-8E65C5077CAAQ34020530-E907FE12-2960-465D-9C9C-7D42AAAA6182Q34090268-29557845-A1DC-4B81-9521-0939DC70D1D9Q34172530-774D2732-7200-4C6A-9F4E-DA0823AAAB55Q34242291-3F79DF71-A5D2-4EF4-A19A-2C58FA13379BQ34393660-D5B0D76A-4149-4773-949D-6E29AA94DBB8Q34601985-9A9CDF3D-A5C5-408E-A6A5-A5695E2ED970Q34622554-849B9C31-1460-4E25-94F3-895215BE2333Q35155222-F3A790FA-A789-4D6C-85F7-58651BA271DFQ35587147-55A360A2-C179-45F0-A1F1-A5081BBF893AQ35607871-3FE5E229-B28A-4E28-B6AB-ACADC6FF5D3DQ35822254-09298D17-5371-4BA7-932D-C2128069EE63Q36032742-72D5363A-9FB6-4743-943C-592E94BF7EA6Q36171916-08DB4B97-978C-407B-A43C-B30ECC4DF969Q36213275-3337EE26-8F05-442A-9BB0-0D8B3D6A4FD3Q36263511-8BA56A19-8719-4744-8294-29702C5CF8F2Q36359270-3816E79B-E7F2-4CB2-9D35-A33C377ECE68
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Chemotherapy of trypanosomiases and leishmaniasis.
@ast
Chemotherapy of trypanosomiases and leishmaniasis.
@en
type
label
Chemotherapy of trypanosomiases and leishmaniasis.
@ast
Chemotherapy of trypanosomiases and leishmaniasis.
@en
prefLabel
Chemotherapy of trypanosomiases and leishmaniasis.
@ast
Chemotherapy of trypanosomiases and leishmaniasis.
@en
P2093
P356
P1476
Chemotherapy of trypanosomiases and leishmaniasis.
@en
P2093
Julio A Urbina
Michael P Barrett
Simon L Croft
P304
P356
10.1016/J.PT.2005.08.026
P577
2005-09-08T00:00:00Z